Skip to main content
. 2015 Dec 10;112(52):16018–16023. doi: 10.1073/pnas.1522150112

Fig. 4.

Fig. 4.

Rapid effects of estrogens and receptor agonists on CA1 AMPA- or NMDA-induced membrane depolarization. (A and D) Treatment protocol for (S)-AMPA or NMDA induced depolarization measures. (B and E) Percent baseline of membrane depolarization amplitude elicited by (S)-AMPA or NMDA; mean ± SEM. (B) Fifteen to 20 min of 50 nM 17β-estradiol decreases AMPA-mediated membrane potential amplitudes (F3, 19 = 4.05, P < 0.05, post hoc q = 4.45, df = 8, P < 0.05). One-hundred nanomolars or 150 nM of PPT also decreases AMPA-mediated membrane depolarization (F3, 25 = 3.33, P < 0.05, post hoc for 100 nM q = 3.91, df = 14, P < 0.05, and for 150 nM q = 3.73, df = 13, P < 0.05). DPN does not affect AMPA membrane depolarization amplitude. (E) Hormone treatments do not affect NMDA induced membrane depolarization. (C and F) Membrane potential traces. Black boxes indicate length and duration of (S)-AMPA or NMDA agonist application. [Scale bars, 2 mV (vertical axis) and 1 min (horizontal axis).] *P < 0.05.